PodcastPearls: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Downloadable slides accompanying a podcast led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, about how they use CDK4/6 inhibitors for patients with HR-positive/HER2-negative breast cancer, including key studies on CDK4/6 inhibitors from ASCO 2021.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 643 KB
Released: August 24, 2021


Produced in collaboration with
Supported by an educational grant from

For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.

Related Content

Commentary from Dr. Sunil Badve on Ki67 testing for patients with early-stage hormone receptor-positive/HER2-negative breast cancer from the American Society of Clinical Pathology (ASCP) and Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Released: December 28, 2021

Downloadable summary slideset with key data from the 2021 SABCS Symposium from Clinical Care Options (CCO)

Released: December 16, 2021

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see

Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings